$CMPX SEC Filings

Filed On	Filing
02 Oct 2026	Form 4: Lerner Neil, Chief Accounting Officer Bought 20,000 shares ($18.4K)
25 Sep 2026	Form 4: Lerner Neil, Chief Accounting Officer Bought 2,500 shares ($2.85K)
22 Sep 2026	8-K: Regulation FD Disclosure BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today...
14 Aug 2026	SCHEDULE 13G/A
07 Aug 2026	SCHEDULE 13G
06 Aug 2026	FORM 10-Q
06 Aug 2026	8-K: Results of Operations and Financial Condition
01 Jul 2026	8-K: Regulation FD Disclosure
23 Jun 2026	8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
11 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
15 May 2026	SCHEDULE 13G/A
05 May 2026	FORM 10-Q
05 May 2026	8-K: Results of Operations and Financial Condition
30 Apr 2026	Form 4/A: Lerner Neil, Chief Accounting Officer Bought 15,000 shares ($28.4K)
30 Apr 2026	Form 4/A: Anderman Jonathan, General Counsel Bought 25,000 shares ($47.3K)
29 Apr 2026	Form 4: Anderman Jonathan, General Counsel Received 25,000 shares as a grant or award ($47.3K)
29 Apr 2026	Form 4: Lerner Neil, Chief Accounting Officer Received 15,000 shares as a grant or award ($28.4K)
29 Apr 2026	ARS
29 Apr 2026	DEFA14A
29 Apr 2026	Proxy statement: annual meeting on June 10, 2026 CEO pay $5.1M, up 65% · say-on-pay vote

Comments